Related Experiment Videos
[Clinical trial with a nonamphetaminic anoretic]
Revista Iberica De Endocrinologia
|September 1, 1976
Summary
A new tricyclic compound, mazindol, was evaluated for its appetite-suppressing effects in overweight patients. The eight-week study compared mazindol
Area of Science:
- Pharmacology
- Clinical Medicine
- Obesity Research
Background:
- Obesity is a significant global health concern.
- Pharmacological interventions are sought to manage overweight and obesity.
- Existing treatments may have limitations or side effects.
Purpose of the Study:
- To investigate the anorexigenic (appetite-suppressing) activity of a novel tricyclic compound, mazindol.
- To assess the efficacy of mazindol in patients with mild to moderate overweight.
- To compare mazindol's effects against a placebo in a controlled clinical setting.
Main Methods:
- A randomized, placebo-controlled trial was conducted over eight weeks.
- Participants included 20 overweight patients receiving mazindol and 20 receiving placebo.
- Patient demographics included age range (16-55 years) and minimum overweight of 15% above ideal body weight.
Main Results:
- The study evaluated the anorexigenic potential of mazindol.
- Mazindol is a tricyclic compound distinct from amphetamines.
- The treatment duration was eight weeks for both mazindol and placebo groups.
Conclusions:
- Mazindol demonstrated potential as an anorexigenic agent.
- Further research is warranted to establish its therapeutic role in weight management.
- The compound's non-amphetamine nature may offer a different safety profile.